Skip to main content
Clinical Trials/NL-OMON43478
NL-OMON43478
Completed
Not Applicable

Assessing cholinergic innervation in Parkinson*s disease using the PET imaging marker [18F]Fluoroethoxybenzovesamicol - Cholinergic PET imaging in Parkinson*s disease

niversitair Medisch Centrum Groningen0 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Control Subjects:
  • \- Age between 45 \- 65 years
  • \- Willingness to cooperate and sign written informed consent
  • \- No prior history of neurologic or psychiatric illness
  • \- Able and fit enough to participate in this study;Patient Group:
  • \- Diagnosis Parkinson\*s disease
  • \- Disease duration between 3 and 10 years.
  • \- Age between 45 \- 65 years
  • \- Willingness to cooperate and sign written informed consent

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • \- The refusal to be informed about an unforeseen clinical finding
  • \- Pregnant women, breast feeding
  • \- Exhibition to a radiation dose for other reasons (e.g. participation in other research trial), exceeding the maximum annual dose.
  • \- Anticoagulant medication, antiplatelet agents used in the 5d before the imaging visit
  • \- Contra\-indication for MRI\-scanning (metal parts in the body)
  • \- Other neurological conditions, more specifically neurodegenerative disorders and brain lesions.
  • \- Treatment with deep brain stimulation

Outcomes

Primary Outcomes

Not specified

Similar Trials